secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055203
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance
-----------------------------------------------------------------------

- Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).
- CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.
- FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.
- Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.
- CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/0001104659-26-055203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer